Cardiovascular Systems Inc. named Kevin Kenny to the newly created position of executive vice president of sales and marketing. The New Brighton, Minnesota-based medical device company, which develops and sells solutions for treating vascular and coronary disease, said that Kenny would oversee all sales and marketing functions. Previously, Kenny held several positions at Medtronic, most […]
Cardiovascular Systems Inc. recently announced that it’s started a limited-market release of its Stealth 360° Orbital PAD System, the latest in the company’s line of catheter-based systems that rub away plaque in clogged arteries in the pelvis or leg. St. Paul, Minnesota-based CSI (NASDAQ:CSII) claims the Stealth 360° has a simpler, more user-friendly design than […]
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Cardiovascular Systems Inc. (CSI), based in New Brighton, Minnesota, has raised $5 million from the sale of debt, according to documents filed with the Securities and Exchange Commission. In 2008, CSI filed an initial public offering (IPO), hoping to raise $86.3 million to help expand sales of its Diamondback 360 device, which removes plaque from peripheral vessels in the pelvis or leg.
Cardiovascular Systems Inc. (NASDAQ:CSII) and local rival ev3 Inc. have called a truce. CSI, based in St. Paul, Minnesota, said Tuesday it has settled an employment lawsuit with ev3, headquartered in Plymouth. The suit, filed by ev3 in 2007, accused CSI of poaching two unspecified employees.
Ernie Andberg has a little more free time on his hands these days. The long-time “emerging medical device companies” equity analyst for Feltl & Co. in Minneapolis has not seen a lot of companies emerging lately. In fact, they’ve been disappearing all together. Case in point: Medtronic Inc.’s (NYSE: MDT) deal last week to acquire […]
The trial is intended to evaluate the system's safety and effectiveness for the treatment of calcified coronary lesions -- formations of plaque that reduce blood flow in coronary arteries.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.